Windtree Signs Strategic Deal To Support Revenue And Advance Therapeutic Pipeline

Windtree Therapeutics, Inc., a biotechnology company working to generate revenue while advancing innovative therapies for serious medical conditions, has announced that it has entered into an Assignment and Conditional Assumption Agreement with an experienced real estate investment group. Through this agreement, Windtree has secured the rights to acquire a 436-unit multifamily residential property located in Houston, Texas. The property is expected to provide steady rental income as the company continues its work on developing treatments in its pipeline.

The acquisition is planned to be carried out through a separate, wholly owned subsidiary of the company. This new division is also expected to bring in additional management personnel. The purchase will primarily be financed through non-recourse secured mortgage funding, with the remaining amount covered by proceeds from the issuance of preferred stock. Completion of the deal is subject to standard due diligence on the property and the finalization of acceptable financing terms. The company has set a target closing date of May 23, 2025, with the flexibility to extend the deadline twice, each for up to 30 days.

Jed Latkin, Chief Executive Officer of Windtree, said in a statement, “Windtree is expected to become a revenue generating company and these additional assets are intended to diversify and stabilize the Company. By identifying opportunities to bring in stable revenue, we believe the Company can reduce its need for capital that could be dilutive to the stock price. We are actively looking at multiple acquisition candidates that could provide near term revenue and profits. We will continue in our mission to help patients in need with our existing unique drug candidates in cardiogenic shock, heart failure and cancer. We believe that this new approach will allow the Company to grow and limit future stockholder dilution.”

As part of its broader corporate strategy, Windtree aims to acquire revenue-generating assets, which may include income-producing real estate and smaller biotechnology companies with FDA-approved products. While expanding into these areas, the company remains committed to advancing its drug development programs in cardiovascular and oncology-related diseases.